Actual Medicinal Product (AMP) Mycobutin 150mg capsules (Pfizer Ltd)

Stability Information

(Some stability information inherited from generic)

Stability
compatible_special_measures logo Lack of data and/or stability concerns exist. MCA use may be acceptable but is likely to be off-label and require mitigation measures. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or up to 8 weeks if the MCA is airtight (sealed). Consider the risk of potency loss or dose variability and monitor for changes in efficacy or adverse effects after MCA initiation.
Notes

Protect from light. No stability data in MCAs available.

Provenance

This recommendation is based on the products Mycobutin 150mg capsules (Pfizer Limited).

Generic
Rifabutin
Formulation
Rifabutin 150mg capsules
  • Rifabutin
    • Rifabutin 150mg capsules

      • Mycobutin 150mg capsules (Pfizer Ltd)



Related Formulations (1)

compatible_special_measures logo Rifabutin 150mg capsules